Lofexidine

Arnasi Group, Formerly LiquiGlide, Unveils Transformation into a Commercial Brand Company with New Management and Direction

Retrieved on: 
Thursday, November 2, 2023

Beyond the immense potential of LiquiGlide® technology, Salain believes that thoughtful internal brand development will help Arnasi™ address unmet patient and consumer needs through elevated product experiences.

Key Points: 
  • Beyond the immense potential of LiquiGlide® technology, Salain believes that thoughtful internal brand development will help Arnasi™ address unmet patient and consumer needs through elevated product experiences.
  • He is accompanied by Dr. Noah Wolfson, VP of program management, and Dr. Brienne Engel, director of business development.
  • Wolfson has developed brand strategies for more than eight pre-commercial and commercial products, while Engel has facilitated hundreds of collaborations between academic, biotech, and pharmaceutical partners.
  • “We have such broad experience across categories, informing our focus on biomedical and CPG brand launches.”

Spark Biomedical, Inc. Granted $2.49M from the National Institutes of Health for a Clinical Trial Looking at Extended Use of Wearable Neurostimulation in Opioid Use Disorder Treatment

Retrieved on: 
Tuesday, November 16, 2021

However, treatment efficacy and patient retention have been limited meaning significantly fewer patients are using or seeking these non-opioid treatment options.

Key Points: 
  • However, treatment efficacy and patient retention have been limited meaning significantly fewer patients are using or seeking these non-opioid treatment options.
  • Through its upcoming clinical trial, Spark Biomedical ultimately seeks to broaden the footprint of readily available, effective treatment for acute withdrawal and long-term recovery support.
  • Research will be supported by the National Institute On Drug Abuse of the National Institutes of Health under Award Number 1R44DA053876-01.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

US WorldMeds Announces Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic

Retrieved on: 
Thursday, July 9, 2020

LOUISVILLE, Ky., July 9, 2020 /PRNewswire/ --USWM LLC dba US WorldMeds (USWM), a Kentucky-based company, has today announced their partnership with the Federal Emergency Management Agency (FEMA) and Healthcare Ready in bringing urgently needed opioid withdrawal medication to communities in need during the current coronavirus pandemic.

Key Points: 
  • LOUISVILLE, Ky., July 9, 2020 /PRNewswire/ --USWM LLC dba US WorldMeds (USWM), a Kentucky-based company, has today announced their partnership with the Federal Emergency Management Agency (FEMA) and Healthcare Ready in bringing urgently needed opioid withdrawal medication to communities in need during the current coronavirus pandemic.
  • While not a treatment for OUD, LUCEMYRA is the only non-opioid medication approved by the FDA for treatment of opioid withdrawal symptoms*.
  • *LUCEMYRA will not completely prevent the symptoms of opioid withdrawal and is not a treatment for Opioid Use Disorder.
  • COVID has highlighted how left behind our patients have been in the pandemic with substance use disorder rates rising.

US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference

Retrieved on: 
Tuesday, September 4, 2018

LUCEMYRA is the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

Key Points: 
  • LUCEMYRA is the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
  • "Salix will be sharing various, new data sets across our portfolio at PAINWeek, the nation's largest pain conference.
  • LUCEMYRA is not an opioid drug and is not a treatment for Opioid Use Disorder (OUD) (sometimes known as opioid addiction).
  • In clinical trials, LUCEMYRA significantly reduced the severity of withdrawal symptoms compared to placebo, as reported by patients experiencing opioid withdrawal.

US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets

Retrieved on: 
Monday, August 6, 2018

In June, US WorldMeds and Salix Pharmaceuticals entered into an exclusive co-promotion agreement for LUCEMYRA.

Key Points: 
  • In June, US WorldMeds and Salix Pharmaceuticals entered into an exclusive co-promotion agreement for LUCEMYRA.
  • "We share US WorldMeds' enthusiasm and confidence that LUCEMYRA can help the millions who develop Opioid Withdrawal Syndrome find meaningful relief."
  • The launch includes a co-pay program that provides LUCEMYRA to eligible patients for as little as $25.
  • LUCEMYRA is not an opioid drug and is not a treatment for Opioid Use Disorder (OUD) (sometimes known as opioid addiction).

Camargo Congratulates US WorldMeds on Obtaining FDA Approval for the First Non-Opioid Medicine for the Management of Opioid Withdrawal Symptoms

Retrieved on: 
Monday, July 9, 2018

US WorldMeds partnered with Camargo for regulatory support and expertise in developing this innovative approach to managing opioid withdrawal symptoms.

Key Points: 
  • US WorldMeds partnered with Camargo for regulatory support and expertise in developing this innovative approach to managing opioid withdrawal symptoms.
  • On May 16, 2018, the FDA approved the first non-opioid medication, LUCEMYRA, targeted specifically to treat the physical symptoms associated with opioid withdrawal.
  • Camargo supported US WorldMeds with drug development services, especially Chemistry, Manufacturing, and Controls (CMC) and regulatory consulting services.
  • "We appreciate the guidance and insights provided by Camargo," said Kristen Gullo, Vice President, Development and Regulatory Affairs at US WorldMeds.

Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine)

Retrieved on: 
Tuesday, June 26, 2018

Opioid withdrawal is an often-overlooked medical challenge in the current opioid epidemic, which has reached dangerous levels.

Key Points: 
  • Opioid withdrawal is an often-overlooked medical challenge in the current opioid epidemic, which has reached dangerous levels.
  • From a clinical standpoint, symptoms of withdrawal are one of the most powerful drivers of opioid dependence and addictive behaviors.
  • LUCEMYRA is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
  • You may have symptoms of opioid withdrawal during treatment with RELISTOR including sweating, chills, diarrhea, stomach pain, anxiety, and yawning.